Accro Bioscience key facts
as of Oct 2026- Developer of small molecule innovative drugs designed for inflammatory, autoimmune diseases and cancer.
- Accro Bioscience is valued at approximately $161.0M as of Oct 2026 (last reported valuation).
- It has raised $62.0M; the latest was Later Stage VC ($12.0M) in Mar 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Shenzhen Capital Group, Hefei Innovation Technology Venture Capital, 5Y Capital, Hongtai Capital Holdings — 10 tracked in total.
- Status: Privately Held (backing).
Accro Bioscience's last reported valuation, Jan 2022. Nothing priced has surfaced since.
- ·Watch Accro Bioscience: the Monday email on marks, rounds and moves
Accro Bioscience funding rounds
No funding rounds for Accro Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Accro Bioscience valuation
Accro Bioscience's last reported valuation was $161 million in Jan 2022. No priced round, secondary trade or fund mark has surfaced since.
Accro Bioscience investors
10 investors are on record for Accro Bioscience, including Suzhou Oriza Holdings Corporation, Shenzhen Capital Group, Hefei Innovation Technology Venture Capital and 5Y Capital. By type, the record holds 4 venture capital firms and 1 asset manager.
About Accro Bioscience
Developer of small molecule innovative drugs designed for inflammatory, autoimmune diseases and cancer. The company focuses on the molecular mechanism of regulated cell death and the related pathogenesis in human diseases, improving the current therapeutic standard of targeted disease areas.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2017
- Website
- accropeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.